Growth Metrics

Hyperfine (HYPR) Non-Current Debt (2020 - 2026)

Hyperfine posted quarterly Non-Current Debt of $13.1 million for Q1 2026, up 7272.47% on a QoQ basis from $178000.0 in Q4 2020.

Hyperfine (HYPR) has 2 years of Non-Current Debt data on file, last reported at $13.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $13.1 million; the trailing twelve-month figure through Mar 2026 stood at $13.1 million (changed N/A YoY), and the FY2020 full-year result was $178000.0, changed N/A from the prior year.
  • Non-Current Debt for Q1 2026 stood at $13.1 million, up from $178000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $13.1 million in Q1 2026 and bottomed at $13.1 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 29.64 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 14.22 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 27.88 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 10.99 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 598.50 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 8.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 10.13 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 1.81 Bn
10 Hyperfine 149.47 Mn 108.20 Mn 1.98 Mn 13.12 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 13.12 Mn
Mar 31, 2026 13.12 Mn
Dec 31, 2020 178,000.00
Dec 31, 2020 178,000.00